APDN Stock Overview
A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Applied DNA Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$14.40 |
| 52 Week Low | US$0.12 |
| Beta | 0.46 |
| 1 Month Change | 13.89% |
| 3 Month Change | -80.74% |
| 1 Year Change | -98.60% |
| 3 Year Change | -99.79% |
| 5 Year Change | -99.80% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%
Dec 20
Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?
Jan 01Applied DNA climbs 51% after winning large purchase order
Oct 10Applied DNA stock rises 12% on launching monkeypox testing service in New York
Sep 06Applied DNA adds 17% as company seeks approval for monkeypox test in New York
Aug 19Shareholder Returns
| APDN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.4% | 2.3% | 2.8% |
| 1Y | -98.6% | -5.6% | 24.5% |
Return vs Industry: APDN underperformed the US Life Sciences industry which returned -5.6% over the past year.
Return vs Market: APDN underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| APDN volatility | |
|---|---|
| APDN Average Weekly Movement | 27.5% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APDN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APDN's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 47 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
| APDN fundamental statistics | |
|---|---|
| Market cap | US$9.37m |
| Earnings (TTM) | -US$7.23m |
| Revenue (TTM) | US$3.43m |
2.7x
P/S Ratio-1.3x
P/E RatioIs APDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APDN income statement (TTM) | |
|---|---|
| Revenue | US$3.43m |
| Cost of Revenue | US$2.41m |
| Gross Profit | US$1.02m |
| Other Expenses | US$8.24m |
| Earnings | -US$7.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 09, 2025
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 29.63% |
| Net Profit Margin | -210.57% |
| Debt/Equity Ratio | 0% |
How did APDN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 03:44 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Applied DNA Sciences, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jan Wald | Benchmark Company |
| Matthew Miller | CFRA Equity Research |
| Yi Chen | H.C. Wainwright & Co. |